# Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

> **NCT06018688** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 44 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Gene Mutation

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT06018688
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-15
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06018688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06018688, "Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06018688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*